信达生物:IBI363/TAK-928第三项关键注册临床研究完成首例受试者给药

智通财经
Aug 06
【信达生物:IBI363/TAK-928第三项关键注册临床研究完成首例受试者给药】8月6日,信达生物制药集团宣布,其全球首创PD-1/IL-2α-biased双特异性抗体融合蛋白IBI363联合贝伐珠单抗,对比研究者选择治疗,用于治疗既往标准治疗失败或不耐受的晚期结直肠癌的关键注册临床III期研究,完成首例受试者给药。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10